Subtype
High-Grade Glioma, NOS
CI-CAN-00009391Explore in graph →
75 active trials2 approved drugs11 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00009391Explore in graph →
Clinical trials
173 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (30)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06501911 | A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma | withdrawn | Phase 1 | 0 | University of NebraskaOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT06463184 | Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG) | withdrawn | Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Dec 4, 2024 | clinicaltrials |
| NCT05082493 | A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas | withdrawn | Phase 1 | 0 | WPD Pharmaceuticals Sp. z o.o.INDUSTRY | 0 | Jun 6, 2024 | clinicaltrials |
| NCT02598011 | A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care(Toca7) | withdrawn | Phase 1 | 0 | Tocagen Inc.INDUSTRY | 0 | Mar 30, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jul 22, 2025source: clinicaltrials